Objective: We aimed to investigate homocysteine levels and carotid intima-media thickness (CIMT) in Parkinson's Disease (PD), to determine relationship of these parameters and as well as to determine whether CIMT in patients with PD was associated to age, disease duration, age of disease onset, stage, the Unified Parkinson Disease rating scale (UPDRS), the drugs used in therapy.
Introduction

Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disorder after
Alzheimer's Disease [1] . Various studies have reported that the treatment of IPD with levodopa is associated with the elevation of serum homocysteine (Hcy) [2] .
Levodopa is metabolized and changes O-methylation in the brain and peripheral tissues. This reaction is carried out by the means catechol O-methyltransferase (COMT) enzyme, and requires S-adenosyl methionine (SAM) as the methyl donor and produces the demethylated product S -adenyl homocysteine (SAH). Then, SAH is converted to homocysteine. Homocysteine is converted back to methionine via methylene tetra hydro folate reductase and betaine homocysteine methyltransferase.
Methylene tetra hydrofolate reductase requires a folate cofactor. The catabolism of levodopa interferes with homocysteine metabolism at several steps [3] .
Some studies have stated that the toxic effects of hyperhomocysteinemia (HHcy) have been suggested in cardiovascular and cerebrovascular diseases [4] . HHcy is an independent risk factor for coronary artery disease [5] . Elevated Hcy levels may be a risk factor for atherothrombotic vascular disease; this condition may worsen the course of IPD. Intima media thicknes (IMT) is one of the markers of early atherosclerosis and large peripheral arteries can be evaluated for early atherosclerosis [6, 7] . Structural, functional, and hemodynamic alterations of the carotid artery are measured with ultrasound and is used as a marker of atherosclerosis [8] .
The aim of this study was to determine Hcy levels in IPD, to investigate the relationship between Hcy levels and carotid intima media thicknes (CIMT), to determine whether CIMT in patients with IPD was associated with age, disease duration, age of disease onset, stage, Unified Parkinson's Disease rating scale (UPDRS), and the drugs used in therapy, and Hcy levels. and coronary artery disease) were examined by measurements made CIMT according to age groups [12] . The study was approved by the institutional ethics committee of Ordu University.
Anti-parkinsonian treatments were recorded and the total daily dose of levodopa was calculated for each patient. For dopaminergic agonists, we calculated the equivalent levodopa dosage as follows: 4 mg ropinirole=1 mg pramipexole= 100 mg levodopa [13, 14] .
Blood Tests
Blood samples were collected in gel tubes that did not include anticoagulant to measure total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and uric acid (UA); additionally, EDTA tubes were used to measure Hcy after 12 hours overnight.
Blood samples were centrifuged at 1800*g for15 minutes and plasma and serum samples were obtained.
Total cholesterol, TG, HDL-C,LDL-C, and UA levels were measured cholorometrically using an Abbott original reagent on Abbott Architect 8000 auto analyzer. Plasma Hcy was also determined by tandem mass spectrometry (LC-MS/MS).
Ultrasonographic Study
The ultrasound evaluation of the common carotid artery (CCA) was performed as described previously using an (Hitachi Preirus, Tokyo, Japan) that The subgroups of drugs (levodopa+DDEI, levodopa+DDEI+entacapone, and other drugs) were compared each other and significant differences were found in terms of age, age of disease onset, Hcy, UPDRS total, UPDRS motor sections, UPDRS activities of daily living and mean levodopa dosage as given details below (Table 3) . Post hoc analysis was performed to determine which group differences is (groups were compared in pairs)
By comparing the levodopa+DDEI with the levodopa+DDEI+entacapone subgroup ,we have In term of CIMT, no difference was detected among the drug subgroups.
The subgroups with Hcy level of > 15 and ≤ 15 µmol/l were compared and Hcy levels and mean levodopa dosage were significantly higher; HDL-C levels were significantly lower in the subgroup with a homocysteine level > 15. In terms of CIMT and UPDRS scores no significant difference was detected between the subgroups (Table 4) . We have found that the mean age, age of onset of the disease as well as duration of disease in the dopamine agonist group were significantly lower in compared to the other drug groups. This can be related in our patients, dopamine agonists and MAO inhibitors were applied usually at early stages in younger patients.
(H.Y.S.) n (%)
In this respect, we have revealed that UPDRS total, UPDRS motor sections and UPDRS activities of daily living of the patients using dopamine agonists were significantly lower than the other drug subgroups showed lower plasma Hcy concentrations compared to levodopa-treated patients [18] . Nevrly et al. found that the addition of entacapone to the treatment regimens of patients using levodopa resulted in lower homocysteine levels only when compared to the patients using levodopa [19] .In the present study, we demonstrated higher homocysteine levels only in the group using levodopa+DDEI when compared to the group using levodopa+DDEI+entacapone.
Plasma Hcy levels usually range between 5 and 15 µmol/l in healthy adults. Hyperhomocysteinemia (HHcy) may be classified as moderate (15-30μmol/L), intermediate (31-100 µmol/l), and severe (>100 µmol/l) [20] . In our study, Hcy levels were 13.80±3.65 in
Parkinson's patients, among which 12 patients were using levodopa+DDEI+entacapone and 13 patients using other drugs. Only half of our patients were using levodopa and dopamine decarboxylase enzyme inhibitors. Hcy elevations are expected to occur more frequently in the patients using this combination; therefore, the levels in these patients might have affected the mean level, which turned out to be low. .We also demonstrated a positive correlation between age and CIMT, although the level of significance was at the limit.
Conclusion:
We have found significantly increased Hcy levels 
